Cargando…
Switching Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety
Introduction: Most chronic hepatitis B (CHB) patients in China are primitively treated with a combination of lamivudine (LAM) and adefovir dipivoxil (ADV). Although antiviral resistance can be avoided with this combination therapy, using it can have harmful side effects related to ADV, specifically...
Autores principales: | Lian, Jiang-Shan, Zhang, Xiao-Lin, Lu, Ying-Feng, Chen, Jian-Yang, Zhang, Yi-Min, Jia, Hong-Yu, Zhang, Zhe, Yang, Yi-Da |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6332476/ https://www.ncbi.nlm.nih.gov/pubmed/30662324 http://dx.doi.org/10.7150/ijms.28700 |
Ejemplares similares
-
De novo entecavir+adefovir dipivoxil+lamivudine triple-resistance mutations resulting from sequential therapy with adefovir dipivoxil, and lamivudine
por: Yang, Song, et al.
Publicado: (2016) -
Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015) -
Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy
por: WANG, YANG, et al.
Publicado: (2016) -
Efficacy and resistance in de novo combination lamivudine and adefovir dipivoxil therapy versus entecavir monotherapy for the treatment-naive patients with chronic hepatitis B: a meta-analysis
por: Liu, Fen, et al.
Publicado: (2014) -
Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus
por: Chen, En-Qiang, et al.
Publicado: (2009)